Objective: We prospectively evaluated the rate of postnatal cytomegalovirus (CMV) transmission through breast milk in extremely premature infants to address the impact of CMV infection on preterm infants during lactation.
Introduction
Cytomegalovirus (CMV), a member of the b-herpesvirus subfamily, is the most common cause of congenital and postnatal infections throughout the world. 1 Congenital CMV infection is associated with significant long-term sequelae such as sensorineural hearing loss and mental retardation. 2, 3 In contrast to congenital infections, less focus has been placed on the effects of postnatal CMV acquisition, probably because it is often asymptomatic and thought to result in low morbidity. 4 However, recent studies reporting that postnatal CMV infections in premature infants cause serious clinical symptoms including respiratory compromise, neutropenia, thrombocytopenia, hepatomegaly and septic syndromes have renewed interest in the effects of this pathogen in the immediate postnatal period. [5] [6] [7] Postnatal CMV infection can be acquired through transfused blood, ingestion of infected body fluids such as maternal cervical secretions during the birthing process and breast milk; shedding of CMV in breast milk may represent the main source of postnatal infections. 1 In premature infants, especially extremely premature infants, breast milk is important because it contains protective nutritional and immunological factors. If postnatal CMV infection acquired through breast milk is responsible for serious complications, the avoidance of breast feeding or widespread efforts to achieve viral inactivation should be put into effect. However, symptomatic postnatal CMV infections are seldom observed in Japan. 8 In a previous study, we found that CMV infection occurred in only 3 (10%) of 30 infants who were fed CMV DNA-positive milk, and that none of these infants became symptomatic. 9 These results differed from those reported in a German cohort, [10] [11] [12] probably because of the methods of breast milk preservation or differences in the study population: frozen-thawed milk was mostly used in our study, while raw milk was used in the German cohort, and the mean gestational age and birth weight were slightly greater in our study (mean gestational age, 31 vs 29 weeks; mean birth weight 1360 vs 1100 g). 9 Low birth weight is considered a risk factor for symptomatic CMV infection and may have been responsible for the previous discrepancy. 12 To investigate this issue, we evaluated the rate of CMV transmission through breast milk in extremely premature infants using real-time PCR.
Methods

Study population
This prospective study included breast-fed premature infants and their mothers admitted to Nagoya University Hospital, Nagoya First Red Cross Hospital and Ogaki Municipal Hospital between 1 April 2003 and 30 September 2004. The study included premature infants with a gestational age <28 weeks and/or with a weight <1000 g at birth. All infants were fed their own mother's milk (if available) or donor milk. Exclusion criteria were as follows: congenital CMV infection, defined as infants in whom CMV DNA was detected in urine or serum samples during the first week postpartum; other congenital viral infections; multiple congenital anomalies; hydrops fetalis; congenital heart disease; and infants who were too sick to enter the study and excluded based on the judgment of the attending physician.
Enteral feeding of premature infants was started once their general condition stabilized (range, 0 to 6 days after birth; mean, 1.6 days). During the time mothers were hospitalized, raw breast milk was given to their infants. At our institutes, mothers are usually discharged 5 to 7 days after delivery. After discharge, breast milk supplied by the mothers was preserved at À20 1C until use. During the first month, when an infant's own mother's milk was not available, they were fed donor milk with parental consent. Donor milk was supplied, with the donor's consent, by other patients' mothers within each institution. Milk donors were screened for several viruses (hepatitis B, hepatitis C, human T-lymphotropic virus type 1, human immunodeficiency virus type 1 and type 2), but were not screened for CMV. Donor milk was supplied for one patient by one donor and was preserved at À20 1C. After the first month, infants were either continued on their own mothers' breast milk or changed to formula if donor milk had been used. Infants were then followed until the time of discharge. Discharge criteria included respiratory stability and sufficient weight gain, defined as a total body weight >2500 g. The ethics committee of each institution approved the study and written informed consent was obtained from all parents or guardians before enrollment.
Sample preparations
From each mother, blood samples were collected for CMV antibody tests within the first week postpartum; colostrum was collected; and breast milk samples were collected every 2 weeks until the infants were discharged. From each infant, blood and urine samples were collected within 1 week after birth to screen for congenital CMV infections; blood and urine samples were then collected every 2 weeks until discharge; at discharge, another blood sample was collected for CMV antibody testing. When infants were given donor milk, donor milk samples were collected every 2 weeks for screening. In cases in which infants received blood transfusions, a portion of the blood product was collected for testing. All blood products transfused were leukodepleted by filters. Colostrum, breast milk, donor milk, blood products for transfusion, serum and urine samples were all stored at À20 1C before use.
Clinical data collection
Clinical findings such as feeding intolerance, abdominal distension, hepatomegaly, petechiae, apnea and hypotension were evaluated and recorded by the respective attending physician. Blood samples were taken from infants every week to screen for laboratory abnormalities such as neutropenia, thrombocytopenia, liver enzyme elevation and hyperbilirubinemia. The respective attending physicians were blinded to the results of the breast milk PCR tests and the mother's CMV serologic status.
Serology
Anti-CMV immunoglobulin (Ig) G and IgM antibodies were identified using an enzyme immunoassay kit (Denka Seiken, Tokyo, Japan).
Real-time quantitative PCR assay DNA was extracted from 200 ml of the infants' serum, blood product, and unfractionated breast milk using a QIAamp Blood Kit (Qiagen, Hilden, Germany), and eluted in 100 ml of distilled water. DNA was extracted from 140 ml of the infants' urine samples using a QIAamp Viral RNA kit (Qiagen) and eluted in 100 ml of distilled water.
For each extracted DNA sample, real-time PCR was performed to quantify the CMV DNA copy number. The PCR primers and probes used for this assay were designed to target the CMV immediateearly gene. 13 Real-time PCR was performed using a TaqMan PCR Kit and Model 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA), as described previously. 9, 14, 15 The detection limit of this assay was 100 copies ml -1 .
UL144 gene amplification and DNA sequencing When CMV DNA was detected in urine or serum samples, sequencing of the UL144 gene was conducted. The UL144 gene was amplified by nested PCR. The following PCR primers were used: outer forward primer (5 0 -TCGTATTACAAACCGCGGAGAG GAT-3 0 ), outer reverse primer (5 0 -ACTCAGACACGGTTCCGTAA-3 0 ), inner forward primer (5 0 -CTTCCGGTAGGCATGAA-3 0 ) and inner reverse primer (5 0 -GACTTAATCGTACCGTGA-3 0 ). 16 The PCR products were sequenced directly using a BigDye Terminator Cycle Sequence Kit and ABI PRISM 3100 Automated Sequencer (Applied Biosystems).
Statistical analyses
Differences in categorical variables were analyzed using the w 2 test; differences in the mean values were analyzed with the Mann-Whitney U-test. The statistical analyses were conducted according to intentionto-treat using Statview 5.0 (SAS Institute, Berkeley, CA, USA).
Results
During the study period, 25 mothers and 27 of their infants (two sets of twins) met the entry criteria. The median gestational age was 26.4 weeks (range, 23.7 to 32.6 weeks) and the median birth weight was 802 g (range, 512 to 1108 g). The median observation period was 99 days (range, 70 to 154 days). In all, 14 infants were boys and 13 were girls. Seven infants were delivered vaginally and 20 were delivered by cesarean section. Figure 1 shows the CMV seroprevalence of the mothers in our cohort and the frequency of CMV transmission. In all, 21 of 25 mothers (84%) were seropositive for CMV. In all seropositive mothers, CMV DNA was detected in breast milk. CMV DNA was not detected in the breast milk of seronegative mothers during the study period. Figure 2 shows the CMV DNA copy number in breast milk analyzed by real-time PCR. In total, 7 of 20 colostrum samples (35%) contained CMV DNA. At 2 weeks postpartum, CMV DNA copy number increased and it peaked at 4 to 6 weeks postpartum. CMV DNA shedding in breast milk continued until 8 weeks postpartum. At 10 weeks postpartum, CMV DNA was detected in only one sample; at 12 weeks postpartum, CMV DNA was not detected in breast milk.
In all, 15 of 27 infants were fed donor milk at least once. The donor milk was supplied for one patient by one donor. PCR was performed in a total of 23 samples of donor milk and CMV DNA was detected in 13 of the 23 (57%) samples. As a result, 10 of 15 infants (67%) were fed CMV DNA-positive donor milk. One infant whose mother was seronegative was fed donor milk, but no CMV DNA was detected in the donor milk that the infant received.
In total, 20 of the 27 infants required red blood cell transfusions. The median number of red blood cell transfusions was 2 (range, 1 to 8 times). One of the 27 infants required a platelet transfusion. CMV DNA was not detected in any of the blood samples used for the transfusions.
Of 27 infants, 22 received CMV DNA-positive milk (Figure 1 ). Of these 22 infants, only one infant (4.3%) had detectable CMV levels (recovered in both urine and serum). The male infant who acquired CMV was born by cesarean section at 26 weeks and 5 days gestation. His birth weight was 730 g. He was fed on breast milk for the first 6 weeks of his life and received formula thereafter; he never received donor milk. He received red blood cell transfusions twice, once on day 18 and again on day 23 of life. CMV DNA was first detected on day 70 in both urine and serum samples. He exhibited no clinical symptoms except for a transient elevation of serum aminotransferases (maximum values of aspartate aminotransferase and alanine aminotransferase were 307 IU l -1 and 69 IU l -1 , respectively). Sixteen weeks after birth, both anti-CMV IgM and IgG were detected. The CMV DNA copy number in the breast milk of his mother reached a maximum (4.7 Â 10 4 copies ml -1 ) 6 weeks after birth. This copy number was similar to the mean maximum CMV DNA copy number detected in CMV transmission via breast milk S Hayashi et al breast milk among noninfected infants (2.2 Â 10 4 copies ml -1 ). UL144 gene amplification and DNA sequencing of the infected infant's urine and his mother's breast milk were conducted for strain identification in samples collected at 70 and 28 days after delivery, respectively. The UL144 DNA sequence of each sample matched perfectly. The five infants who were born to seronegative mothers had no CMV DNA in their urine and/or serum at any point during the study period (Figure 1) .
Among the study population, anti-CMV IgM was negative at discharge in all infants but one. Of 21 infants whose mothers had positive anti-CMV IgG, 4 infants were positive for anti-CMV IgG at discharge but 17 infants were negative. In the 4 positive infants, blood samples for CMV antibody tests were collected at a mean of 77 days (range, 70 to 84 days) after delivery, significantly earlier than in the 17 negative infants whose blood samples were collected at a mean of 98 days (range, 70 to 154 days) (P ¼ 0.02). These data suggest the four positive infants had preserved passively transferred anti-CMV IgG from their mothers. All five infants whose mothers were negative for anti-CMV IgG had negative anti-CMV IgG at discharge.
Discussion
Diosi et al. 17 first isolated CMV from breast milk in 1967. Subsequent studies have reported that the rate of virolactia in fractionated milk ranges from 9 to 32%. [18] [19] [20] Recently, maternal CMV reactivation during lactation was analyzed by PCR. [9] [10] [11] [12] [21] [22] [23] In these studies, the rate of CMV DNA-lactia ranged from 87.5 to 97.3%. In our study, all seropositive mothers had CMV DNA in their breast milk. These findings support the notion that CMV reactivation occurs during lactation in most seropositive mothers. We quantified the CMV DNA copy number in breast milk using real-time PCR, and described the longitudinal kinetics of CMV reactivation. In our previous investigation, in which the population was significantly older than in this study (mean gestational ages, 31 vs 26 weeks; P<0.001), 20% of colostrum samples had CMV DNA. 9 At 2 weeks postpartum, CMV DNA was detected at increased levels in breast milk and reached a maximum at 4 to 6 weeks postpartum; in this study, the kinetics of CMV reactivation was almost the same. These data suggest that maternal CMV reactivation does not depend on the gestational age at delivery, and that CMV reactivation during lactation begins 1 to 2 weeks postpartum and ends before 10 weeks postpartum.
We detected CMV DNA in one infant who received CMV-positive milk. To confirm the transmission route, we performed a molecular epidemiologic study. The most widely characterized strain-variant gene in human CMV is glycoprotein B. 24 However, in the past year, the CMV UL144 gene has received considerable attention. UL144 encodes a homolog of the herpes virus entry mediator, a member of the tumor necrosis factor receptor superfamily 1 and may be a genetic marker for human CMV pathogenesis. 25 Lurain et al. 26 reported that UL144 had significant strain-specific sequence variability and we therefore targeted it for strain identification. All sequences identified in mothers' breast milk exactly matched those in their infants' urine samples. Postnatal CMV can be acquired through genital cervical secretions in the birth canal, transfused blood and breast milk. Our single infected infant was born by cesarean section but received blood transfusions twice. All blood products were leukodepleted, and thus CMV was largely eliminated from them; in fact, CMV DNA was not detected in any of the blood samples. By performing molecular characterization of the maternal-infant pair, we confirmed that transmission of CMV occurred through breast milk.
Although breast feeding clearly has a major impact on CMV infection among preterm infants, the ranges of the rates of infection and disease are variable. 7, 11, 27, 28 Hamprecht et al.
11
reported that the rate of CMV transmission through breast milk was 38%, and that 48% of infected infants had symptoms such as hepatopathy, neutropenia, thrombocytopenia and sepsis-like syndrome. In their study, the rate of severely affected infants, with clinical symptoms such as the sepsis-like syndrome, reached 12%. Previously, we reported a transmission rate of only 10% and no infants with clinical symptoms; 9 we assumed that this discrepancy was associated with the older age of the premature infants. In the present investigation, we enrolled more premature infants than we had included previously (gestational age, 31 vs 26 weeks (P<0.001); birth weight, 1360 vs 802 g (P<0.001)). However, despite the increased number of profoundly premature infants, the CMV transmission rate remained extremely low (4.3%), and the single infected infant had few clinical signs. Therefore, we could not attribute the discrepancy between our findings and those of previous investigators to differences in the degree of prematurity.
Another difference between studies was in the method of breast milk preservation. At our institutes, raw breast milk was given to infants for only a few days (during the mothers' period of cohabitation). After the mothers' discharge, breast milk was preserved at À20 1C before use. In the study by Hamprecht et al., 10 raw breast milk was refrigerated at 4 to 10 1C for a maximum of 12 h before feeding. In a prospective study of 38 CMV seropositive mothers and their 42 infants (<35 weeks gestational age; <1500 g birth weight) in Taiwan, the infants largely received frozenthawed breast milk; 6 of 40 infants (15%) exposed to CMV DNApositive breast milk acquired CMV infection, although a sepsis-like syndrome was observed in 5 of the 6 infected infants. 22 In another prospective study of 56 CMV seropositive mothers and 65 of their infants (<1000 g birth weight) in Canada, the infants mainly received frozen-thawed breast milk; 4 of 65 infants (6%) acquired CMV infection, and sepsis-like syndrome was observed in 1 of 4 (25%) infants. 29 In our studies and these, frozen milk was mainly used and the transmission rates were low compared with Hamprecht et al.'s 11 findings. Additional studies that examined the effects of storing CMV-infected breast milk specimens at À20 1C by viral culture 30, 31 found that the storage of breast milk at À20 1C for >3 days reduced the CMV titer by >99%, and storage for >7 days reduced CMV infectivity by 100%. However, no studies performed to date had evaluated the effects of frozen-thawed breast milk in a clinical context. Taken together, 22, 29, 32, 33 these data and our results suggest that frozen-thawed breast milk reduces CMV transmission rates, although differences between ethnic groups and endemic CMV strains must also be taken into account.
Pasteurization may inactivate CMV in breast milk. 20, 32 Hamprecht et al. 34 reported on the reduction of breast milk CMV infectivity by three methods: freeze-thawing, Holder pasteurization and short-time heating for 5 s at 72 1C. CMV infectivity was eliminated in only 1 of 10 samples by freezing milk, but completely eliminated by both Holder pasteurization and short-time heating. However, heating procedures have several problems: heating may have negative effects on breast milk quality, 34, 35 the procedures require special equipment, breast milk is time-consuming to prepare by Holder pasteurization and the possibility that hazardous materials may be eluted from plastic bottles by heating cannot be excluded. Kurath et al. 7 do not recommend general approach, either by avoidance or pasteurization of breast milk, based on low rates of symptomatic disease even in high-risk preterm infants. Instead, to prevent severe infection, they proposed an algorithm for breast-fed preterm infants in case of CMV IgG-positive mother, based on the health status of the preterm infant. 36 In conclusion, according to the kinetics of CMV DNA appearance in breast milk, CMV reactivation starts 1 to 2 weeks postpartum and ends before 10 weeks postpartum. Even in extremely premature infants, CMV transmission rates were low and none of the CMVtransmitted infants developed serious symptoms at our institutes, where frozen milk was mainly used. Frozen-thawed breast milk may decrease the rate of vertical CMV infection and severe disease, although this method cannot completely prevent severe sepsis-like symptoms and necrotizing enterocolitis in rare cases. 5 
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